These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1497 related articles for article (PubMed ID: 15880088)

  • 1. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shigellosis : challenges & management issues.
    Sur D; Ramamurthy T; Deen J; Bhattacharya SK
    Indian J Med Res; 2004 Nov; 120(5):454-62. PubMed ID: 15591629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
    Kotloff KL; Winickoff JP; Ivanoff B; Clemens JD; Swerdlow DL; Sansonetti PJ; Adak GK; Levine MM
    Bull World Health Organ; 1999; 77(8):651-66. PubMed ID: 10516787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shigella isolates of Nepal: changes in the incidence of shigella subgroups and trends of antimicrobial susceptibility pattern.
    Kansakar P; Malla S; Ghimire GR
    Kathmandu Univ Med J (KUMJ); 2007; 5(1):32-7. PubMed ID: 18603983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of isolation of various subtypes and antimicrobial resistance of Shigella from urban slums of Karachi, Pakistan.
    Zafar A; Hasan R; Nizami SQ; von Seidlein L; Soofi S; Ahsan T; Chandio S; Habib A; Bhutto N; Siddiqui FJ; Rizvi A; Clemens JD; Bhutta ZA
    Int J Infect Dis; 2009 Nov; 13(6):668-72. PubMed ID: 19135399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk areas and neighborhood-level risk factors for Shigella dysenteriae 1 and Shigella flexneri.
    Emch M; Ali M; Yunus M
    Health Place; 2008 Mar; 14(1):96-105. PubMed ID: 17602851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of shigellosis in Lagos, Nigeria: trends in antimicrobial resistance.
    Iwalokun BA; Gbenle GO; Smith SI; Ogunledun A; Akinsinde KA; Omonigbehin EA
    J Health Popul Nutr; 2001 Sep; 19(3):183-90. PubMed ID: 11761772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing antimicrobial resistance--an emerging problem in the treatment of shigellosis.
    Niyogi SK
    Clin Microbiol Infect; 2007 Dec; 13(12):1141-3. PubMed ID: 17953700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India.
    Pazhani GP; Ramamurthy T; Mitra U; Bhattacharya SK; Niyogi SK
    Epidemiol Infect; 2005 Dec; 133(6):1089-95. PubMed ID: 16274506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shigellosis in Calcutta during 1990-1992: antibiotic susceptibility pattern and clinical features.
    Bhattacharya MK; Bhattacharya SK; Paul M; Dutta D; Dutta P; Kole H; De D; Ghosh AR; Das P; Nair GB
    J Diarrhoeal Dis Res; 1994 Jun; 12(2):121-4. PubMed ID: 7963341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of Shigella flexneri and S. dysenteriae isolated from stool specimens of patients with bloody diarrhoea in Mwanza, Tanzania.
    Temu MM; Kaatano GM; Miyaye ND; Buhalata SN; Shushu ML; Kishamawe C; Changalucha JM
    Tanzan Health Res Bull; 2007 Sep; 9(3):186-9. PubMed ID: 18087897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive arthritis associated with Shigella dysenteriae type 1 infection.
    Mazumder RN; Salam MA; Ali M; Bhattacharya MK
    J Diarrhoeal Dis Res; 1997 Mar; 15(1):21-4. PubMed ID: 9308297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of drug resistant Shigellosis: a report from Bangalore.
    Srinivasa H; Baijayanti M; Raksha Y
    Indian J Med Microbiol; 2009; 27(4):358-60. PubMed ID: 19736408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiological characteristics of Shigella spp. isolated from river Narmada during 2005-2006.
    Sharma A; Singh SK; Kori L
    J Environ Health; 2009; 71(6):61-6. PubMed ID: 19192746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of current shigellosis treatment.
    Bhattacharya SK; Sur D
    Expert Opin Pharmacother; 2003 Aug; 4(8):1315-20. PubMed ID: 12877639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Shigella species and their antimicrobial resistance patterns in Eastern Nepal.
    Bhattacharya S; Khanal B; Bhattarai NR; Das ML
    J Health Popul Nutr; 2005 Dec; 23(4):339-42. PubMed ID: 16599104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outbreak of dysentery due to nalidixic acid resistant S. dysenteriae 1 at Agartala, Tripura: a hospital based study.
    Datta P; Sen D
    Indian J Public Health; 1990; 34(1):11-4. PubMed ID: 2101382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.